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Abstract
Purpose The aim of this study was to find clinically relevant
MIBG-avid metastatic patterns in patients with newly diag-
nosed stage 4 neuroblastoma.
Methods Diagnostic 123I-MIBG scans from 249 patients (123
from a European and 126 from the COG cohort) were
assessed for metastatic spread in 14 body segments and the
form of the lesions: “focal” (clear margins distinguishable
from adjacent background) or “diffuse” (indistinct margins,
dispersed throughout the body segment). The total numbers of
diffuse and focal lesions were recorded. Patients were then
categorized as having lesions exclusively focal, lesions more
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focal than diffuse, lesions more diffuse than focal, or lesions
exclusively diffuse.
Results Diffuse lesions affected a median of seven body seg-
ments and focal lesions a median of two body segments
(P<0.001, both cohorts). Patients with a focal pattern had a
median of 2 affected body segments and those with a diffuse
pattern a median of 11 affected body segments (P<0.001,
both cohorts). Thus, two MIBG-avid metastatic patterns
emerged: “limited-focal” and “extensive-diffuse”. The median
numbers of affected body segments in MYCN-amplified
(MNA) tumours were 5 (European cohort) and 4 (COG co-
hort) compared to 9 and 11, respectively, in single-copy
MYCN (MYCNsc) tumours (P<0.001). Patients with exclu-
sively focal metastases were more likely to have a MNA
tumour (60 % and 70 %, respectively) than patients with the
other types of metastases (23 % and 28 %, respectively;
P<0.001). In a multivariate Cox regression analysis, focal
metastases were associated with a better event-free and overall
survival than the other types of metastases in patients with
MNA tumours in the COG cohort (P<0.01).
Conclusion Two metastatic patterns were found: a “limited
and focal” pattern found mainly in patients with MNA neuro-
blastoma that correlatedwith prognosis, and an “extensive and
diffuse” pattern found mainly in patients with MYCNsc
neuroblastoma.
Keywords Neuroblastoma .MIBG scan .Metastatic
patterns . Metastases . Outcome
Introduction
In about 90 % of patients with neuroblastoma, 123I-MIBG
scintigraphy reveals both the primary tumour and, in stage 4
neuroblastoma, especially osteomedullary metastases [1].
Two standardized methods for scoringMIBG scans have been
described: the Curie method and the SIOPEN method [2–7].
These are semiquantitative and are used for assessment of
tumour load and for response evaluation. However, no de-
tailed analyses of MIBG-avid metastatic patterns in stage 4
neuroblastoma have been reported. Moreover, as well as the
number of lesions (tumour load) on 123I-MIBG scans at diag-
nosis, osteomedullary lesions can present as focal lesions,
diffuse lesions or both types. So we wondered if these would
represent different types of biological lesion.
As stage 4 neuroblastoma is a heterogeneous disease with
varying outcomes, we hypothesized that different disease
patterns exist in patients with stage 4 neuroblastoma.
Therefore, the aim of this study was to find clinically relevant
MIBG-avid metastatic patterns in patients with newly diag-
nosed stage 4 neuroblastoma.
Materials and methods
Diagnostic 123I-MIBG scans from 249 patients with histolog-
ically proven [8] stage 4 neuroblastoma according to the
International Neuroblastoma Staging System from two patient
cohorts (the European cohort and the COG cohort) were
included retrospectively. The European cohort comprised
123 patients from European collaborative centres diagnosed
between October 1994 and September 2012 (Supplementary
Table 1) and treated with different high-risk protocols: HR-
NBL-1/SIOPEN (26 patients) [9], GPOH NB97 (21 patients)
[10], NBL HR VECI (38 patients) [11], DCOG NBL 2004/
GPOH (38 patients). The COG cohort comprised 126 patients
from the COG A3973 high-risk protocol study diagnosed
between March 2001 and March 2006 [12]. The European
cohort was used as the study cohort, and the COG cohort as
the validation cohort. Clinical patient data, available in the
clinical trial databases of the centres and trial organizations
were used. MYCN status was determined as specified in the
GPOH, SIOPEN and COG trials (Southern blot, fluorescence
in situ hybridization or array-based comparative genomic
hybridization) [13–15].
For the European cohort, the institutional review board
approved this retrospective study and the requirement to ob-
tain informed consent was waived (European cohort) or writ-
ten informed consent was obtained from all patients (or legal
guardians) before study entry (COG cohort).
123I-MIBG scans
Diagnostic whole-body 123I-MIBG scans acquired according
to protocols corresponding with European guidelines and
International Neuroblastoma Risk Group taskforce recom-
mendations were used [1, 6, 16]. Scans were excluded if
metastases were non-MIBG-avid, if body parts were lacking,
if the image count rate was not sufficient for adequate dis-
crimination between body and background (inferior quality),
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if patients were receiving treatment with antihyperten-
sive agents that antagonize the uptake of MIBG by
neuroblastoma cells, and if no scan was available at diagnosis
(Supplementary Table 2).
Method for evaluating 123I-MIBG scans
To be able to investigate metastatic patterns, the number of
affected body segments was recorded (maximum of 14) and
the form of MIBG-avid skeletal lesions was categorized as
“focal” (F) or “diffuse” (D) (Fig. 1a; see Supplementary
Table 3 for an example of the categorization of form). Focal
metastases were hot-spots with clear margins distinguishable
from the background (Fig. 1b). Diffuse metastases had no
clear margins and were spread throughout the body segment
(Fig. 1c). Scans were evaluated by two independent observers
trained by a nuclear medicine radiologist. For the COG cohort
the extension of metastases was also scored according to the
Curie method [2, 6].
Statistical analysis
Interobserver variability was quantified using the kappa coef-
ficient before discordant findings were resolved by consensus.
All reported correlations and outcome analyses were per-
formed on the consensus scores. Correlations were tested for
statistical significance using the Mann-Whitney U test, the
Kruskal Wallis test or Fisher's Exact test. Survival was
analysed using the Kaplan-Meier life-table method for the
COG cohort because this cohort was homogeneously treated
over a fixed time period. The median follow-up was 6.1 years
(1.3 to 9.5 years). Event-free survival (EFS) was calculated as
the time from diagnosis to the first event (relapse, progression,
death) or last examination if no event occurred. Overall sur-
vival (OS) was calculated as the time from diagnosis to death
or last examination. Differences in OS and EFS between
patients with different metastatic patterns were analysed using
the log-rank test. A multivariate Cox regression analysis of the
form of metastases, age, and Curie score, stratified by MYCN
status, was also performed. Therefore metastases were divided
into two categories (dichotomized) according to form (exclu-
sively focal versus the others, i.e. focal≥diffuse +
diffuse>focal+diffuse), and the patients were divided accord-
ing to the cut-off age of 18 months [17] and according to the
median Curie score of 12.
To test the effect of tumour burden at diagnosis on out-
come, the Curie score was determined in the COG cohort, and
outcome was evaluated in term of both previously published
cut-off scores of 2 and 9 [3, 7] and also a cut-off score of 12
(median score in the COG cohort).
Results
Patient characteristics
We included 123 out of 149 of the available diagnostic 123I-
MIBG scans from patients of the European cohort. In the
COG A3973 high-risk cohort, in 306 patients, 91 diagnostic
scans were 131I-MIBG scans. Clinical and biological charac-
teristics of 170 of 215 patients with 123I-MIBG scans were
available and evaluated [12]. Of these 170 123I-MIBG scans,
126 were included. Excluded scans are described in
Supplementary Table 2 for the two cohorts: non-MIBG-avid
metastases in 21 and 20 patients, inferior quality in 2
and 23, use of antihypertensive agents in 2 and 0, and
treatment before the scanning procedure in 1 and 1
patient. The distribution of age and MYCN status was
comparable in both cohorts (Table 1), except exclusion
of patients younger than 12 months with single-copy MYCN
(MYCNsc) neuroblastoma in the high-risk COG cohort. The
characteristics of the excluded patients were comparable in the
two cohorts.
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Fig. 1 Method for evaluating MIBG-avid metastatic patterns (form and
number of affected body segments). a Number of affected body seg-
ments: 1 dome of skull; 2 base of skull; 3 facial bones; 4 ribs, sternum,
scapula and clavicles; 5 vertebral column; 6 pelvis; 7 and 8 upper arms
(left and right); 9 and 10 forearms and hands (left and right); 11 and 12
upper legs (left and right); 13 and 14: lower legs and feet (left and right).
b, c Lesion form: focal (b) lesions imaged as hot-spots with clear margins,
distinguishable from the background; diffuse (c) lesions without clear
margins and uptake spread throughout the body segment
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Focal and diffuse lesions
A total 966 lesions were identified in the European cohort
(123 patients; Table 2) affecting 928 body segments. Of these
lesions, 292 (30 %) were focal and 674 (70 %) were diffuse.
Representative 123I-MIBG scans are shown in Fig. 1b, c. The
292 focal lesions were present in 101 of 123 patients, with a
median of 2 per patient compared to 674 diffuse lesions in 95
of 123 patients with a median of 7 (P<0.0001; Table 2). In the
COG cohort A total of 984 lesions were identified in the COG
cohort (123 patients) affecting 969 body segments. Of these
lesions, 264 (27%) in 95 patients were focal and 720 (73%) in
103 patients were diffuse. Diffuse lesions affected a median of
7 body segments per patient and focal lesions a median of 2
body segments per patient (P<0.0001; Table 2).
“Limited-focal” and “extensive-diffuse” MIBG-avid
metastatic patterns
Patients present with only focal, only diffuse, or both forms of
metastases. The numbers of patients with “exclusively focal”
(focal), “focal more than/equal to diffuse” (focal≥diffuse),
“more diffuse than focal” (diffuse>focal), and “exclusively
diffuse” (diffuse) lesions were recorded. The distributions of
the patterns were very similar in the European and COG
cohorts, with a slight preponderance of the diffuse>focal
pattern (38 % and 39 %), with 23 % and 18 % focal, 21 %
and 18 % focal≥diffuse, and 18 % and 25 % diffuse, respec-
tively (Fig. 2a, b).
The association between the form and the number of
affected body segments were then analysed for each pa-
tient. In the European cohort, focal, focal≥diffuse,
diffuse>focal and diffuse lesions were identified in a
median of 2, 6, 11 and 11 body segments, respectively
(Fig. 2c). There were significant differences between the
form groups in relation to the number of affected body
segments: focal versus diffuse, focal≥diffuse versus
diffuse>focal and focal versus the three other groups, all
P<0.001. In the COG cohort these patterns were very
similar and significant relationships between the form of
metastases and the number of affected body segments
were also seen (Fig. 2d). The actual numbers of focal
and diffuse lesions in each individual patient are shown
in Supplementary Table 4.
“Limited-focal” patterns associated with MYCN
amplification
The differences in MIBG-avid metastatic patterns suggest a
biological difference between the MYCN status groups. We
therefore investigated whether the MYCN gene could be
involved. MYCN status was clearly associated with the num-
ber of affected body segments (Fig. 3) as well as with the form
of metastases (Table 3). Patients with MYCN-amplified
(MNA) tumours had significantly fewer affected body seg-
ments. The median numbers of affected body segments in the
European and COG patients withMNA tumours were 5 and 4,
respectively, and in the European and COG patients with
MYCNsc tumours were 9 and 11, respectively (P<0.001 for
Table 1 Patient characteristics
MYCN status Age European
cohort (n=123)a
COG cohort
(n=126)b
Amplifiedc <12 months 3 2
12–18 months 7 9
18 months to 12 years 28 34
≥12 years 0 0
Unknown 1 0
Total 39 45
Single copy <12 months 16 0
12–18 months 6 4
18 months to 12 years 54 71
≥12 years 2 5
Unknown 0 0
Total 78 80
No data <12 months 0 0
12–18 months 1 0
18 months to 12 years 5 0
≥12 years 0 0
Unknown 0 1
Total 6 1
aMedian age 2.7 years (range 0–16.5 years)
bMedian age 2.9 years (range 0.8–15.2 years)
cMYCN amplification was considered present if eight or more copies
were detected [10–12]
Table 2 Characteristics of
metastatic lesions Focal Diffuse Total P value
European cohort Number of lesions 292 (30 %) 674 (70 %) 966
Number of patients 101 95 123
Lesions per patient, median (range) 2 (1–9) 7 (1–14) <0.001
COG cohort Number of lesions 264 (27 %) 720 (73 %) 984
Number of patients 95 103 126
Lesions per patient, median (range) 2 (1–8) 7 (1–14) <0.001
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both cohorts; Fig. 3). MNA tumour was found in 67 % of
patients (18/27) with focal lesions in the European cohort and
in 70 % of such patients (16/23) in the COG cohort (Table 3).
In contrast, MNA tumour was found in only 23 % of patients
(21/90) in the other metastatic groups (focal≥diffuse +
diffuse>focal + diffuse; P<0.001) in the European cohort
and in 28 % of such patients (29/102; P<0.001) in the COG
cohort.
Prognostic value of MIBG-avid metastatic patterns
Next, we investigated the prognostic impact of the iden-
tified MIBG-avid metastatic patterns. This analysis was
only performed in the COG cohort. The European co-
hort received more variable treatment due to the longer
inclusion period, which might have had an impact on OS and
EFS, but not on the metastatic pattern as these were investi-
gated at diagnosis only.
COG patients with exclusively focal metastases had a small
but statistically significant better OS, but not EFS, than pa-
tients in the other metastatic groups (95 % confidence inter-
vals, CI: 52±20% vs. 35±9 % for 5-year EFS, P=0.191; 73±
19 % vs. 49±10 % for 5-year OS, P=0.050; Supplementary
Fig. 1). Among patients with MNA tumours, those with focal
lesions had a much better EFS and OS than those in the other
metastatic groups (95 % CI: 63±24% vs. 21±15% for 5-year
EFS, P=0.006; 81±20 % vs. 28±17 % for 5-year OS, P=
0.001; Fig. 4a, b). Among patients with MYCNsc tumours, no
c d
a b
Fig. 2 Forms of metastases and
numbers of affected body
segments per patient. a, b
Distribution of forms of
metastases in the European cohort
(a) and the COG cohort (b). The
numbers of patients with focal,
diffuse and both types of lesions
are shown. Patients were
categorized as exclusively focal
(F), exclusively diffuse (D),
focal≥diffuse (F≥D) or
diffuse>focal (D>F). c, d
Relationship between form of
metastases and number of
affected body segments per
individual patient in the European
cohort (c) and the COG cohort
(d). Each data point represents a
patient; the horizontal lines
indicate the median number of
affected body segments
a
b
Fig. 3 Relationship between MYCN status and number of affected body
segments per patient: a European cohort (n=123; six patients no data on
MYCN status). b COG cohort (n=126; one patient no data on MYCN
status). Each data point represents a patient; horizontal lines median
numbers of affected body segments. MNA MYCN amplification,
MYCNsc single-copy MYCN
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significant nor large differences in EFS and OS were
found between those with focal lesions and those in all
other metastatic groups (95 % CI: 29±34 % vs. 41±
12 % for 5-year EFS, P=0.401; 57±37 % vs. 58±12 %
for 5-year OS, P=0.930; Fig. 4c, d).
In the separate multivariate Cox regression analyses in
patients with MNA tumour and those with MYCNsc tumours
the form of metastases in MNA neuroblastomas showed in-
dependent prognostic value in the presence of potential prog-
nostic factors (age and Curie score at diagnosis;
Table 4). Using the Curie score as a dichotomized
variable with previously published cut-off scores of 2
and 9 [3, 7] and also with a cut-off score of 12 (median
score in the COG cohort), did not result in a significant
prediction of outcome in either the univariate or the multivariate
analyses. So correcting for the Curie score did not have impact
on outcome.
We conclude that in patients with MNA tumours,
patients with exclusively focal metastases have a signif-
icantly better outcome than patients with (additional)
diffuse metastases.
Interobserver variability
The interobserver variability in evaluating the 123I-MIBG
scans was “moderate” to “almost perfect”, with median κ
values for affected body segments and for form of metastases
per body segment of 0.9 (0.7–1.0) and 0.5 (0.3–1.0), respec-
tively in the European cohort, and of 0.9 (0.7–0.9) and 0.6
(0.3–0.8), respectively, in the COG cohort (for details see
Supplementary Table 5). The κ value for the form of metas-
tases on a patient basis categorized as focal vs. focal≥diffuse +
diffuse>focal + diffuse was 0.7 (P<0.001) with 89 % concor-
dant findings. All discordant findings were resolved by con-
sensus. Performing all analyses again with single observer
rates did not change the findings.
Fig. 4 Event-free survival (EFS) and overall survival (OS) according to
the form of metastases stratified byMYCN status (a, bMYCN-amplified
tumours; c, d single-copy MYCN tumours). EFS (a, c) and OS (b, d) in
patients with focal lesions (F) versus those with all other types of lesions
(focal≥diffuse + diffuse>focal + diffuse, F≥D + D>F + D). (No at risk
number of patients at risk, i.e. still alive, at the corresponding time points,
y years after diagnosis)
Table 3 MYCN status in relation to the form of metastases
MYCN status European cohort COG cohort
Form Total Form Total
Focal All other
groupsa
Focal All other
groupsa
Amplified 18 21 39 16 29 45
Single copy 9 69 78 7 73 80
Total 27 90 117 23 102 125
P value <0.001 <0.001
a Focal≥diffuse + diffuse>focal + diffuse
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Discussion
This study identified two MIBG-avid metastatic patterns in
patients with newly diagnosed stage 4 neuroblastoma: a “lim-
ited and focal” pattern found mainly in patients with MNA
neuroblastoma, and an “extensive and diffuse” pattern found
mainly in patients withMYCNsc neuroblastoma. The obvious
difference between focal and diffuse metastases is still not
understood. In international guidelines skeletal uptake of
MIBG is reported to be visible as focal or diffuse lesions
[18], and the SIOPEN scoring method distinguishes between
discrete foci and diffuse lesions [6]. In the literature, “focal”
lesions are mostly reported as bone metastases [19, 20] and
“diffuse” lesions as bone marrow metastases [19, 21–24]. As
almost 95% of patients with stage 4 neuroblastoma have bone
marrow involvement at diagnosis, the nature of focal and
diffuse lesions was not studied in our cohort. This needs to
be done in a prospective study, comparing MIBG scintigra-
phy, immunocytological bone marrow involvement and MRI
for anatomical localization of the lesions.
To our knowledge, no classification of stage 4 tumours
based on MIBG-avid metastatic patterns has been described.
The recognition of two different metastatic patterns in stage 4
neuroblastoma suggests that multiple and different underlying
molecular alterations might be involved in the process of
metastases. Indeed the focal pattern was significantly associ-
ated with amplification of MYCN, which is considered a
major tumour-driving gene. Furthermore, only in patients with
MNA tumours, focal metastases were significantly associated
with a more favourable outcome than diffuse metastases, and
in this subset of patients different biological processes might
be identified. Why this phenomenon was not seen in patients
with MYCNsc tumours needs to be studied further.
Amajor question arising from this study is whether MYCN
activity is responsible for the focal growth of metastatic le-
sions, and whether and how it relates to the fewer affected
body segments. Not all patients with predominantly focal
lesions had MNA tumours. However, in another study in our
laboratory a subset of MYCNsc neuroblastomas were found
to have high MYCN protein expression. We hypothesize that
the patients with focal lesions with MYCNsc tumours might
have had this MYCN expression profile [25]. The intriguing
results of this study require substantial biological research,
e.g. association with gene expression and molecular data, and
in vitro and in vivo MYCN manipulation studies, to elucidate
the functional role for MYCN in the metastatic spread of
neuroblastoma cells. MYCN expression has been reported to
correlate with a lower norepinephrine transporter (NET) pro-
tein expression, and in turn a lower NET protein expression
was correlated with low MIBG avidity [26]. As we found that
patients with MNA neuroblastoma had not only a predomi-
nantly focal form of metastases but also significantly fewer
involved body segments on MIBG imaging at diagnosis, we
hypothesize that the lower NET expression in MNA tumours
causes the focal pattern.
Although two well-performing methods for scoring MIBG
scans are used internationally, we developed our own method
of evaluation as a tool to find MIBG-avid metastatic patterns
with a qualitative variable (the form of metastases per body
segment) as the key variable [2, 3, 6] (Supplementary
Table 6). The novelty of our findings is that the form of
metastases at diagnosis, an aspect that is not scored with the
Curie method, was significantly correlated with outcome in
the MNA group. If a prospective study in a homogeneously
treated cohort can confirm the prognostic relevance of the
metastatic pattern in patients with stage 4 neuroblastoma,
eventually patients with stage 4 neuroblastoma might be
subdivided in two risk groups. In addition, in future it might
then be possible to treat patients with different metastatic
patterns according to different treatment protocols that are
more targeted at their biological background.
Although the distinction between focal and diffuse metas-
tases was not always very clear, especially because sometimes
the two forms of metastases were present in one body seg-
ment, all discordant findings could be resolved by consensus.
Furthermore, the results of our correlation and prognostic
analyses were comparable when using single observer scores.
Since the study cohort consisted of 123I-MIBG scans obtained
Table 4 Multivariate Cox regression analysis of survival in the COG cohort stratified by MYCN status
MYCN status Variable 5-year event-free survival 5-year overall survival
Hazard ratio 95 % CI P value Hazard ratio 95 % CI P value
Amplified Age (<18 months vs. ≥18 months) 1.3 0.6–3.0 0.540 1.4 0.6–3.5 0.472
Curie score (<12 vs. ≥12) 1.2 0.5–2.9 0.607 1.2 0.5–2.9 0.679
Form of metastases (focal vs. all other formsa) 0.3 0.1–0.7 0.010 0.2 0.04–0.6 0.005
Single copy Age (<18 months vs. ≥18 months) 0.9 0.2–3.7 0.860 0.5 0.07–3.8 0.497
Curie score (<12 vs. ≥12) 0.7 0.3–1.4 0.291 0.9 0.4–1.9 0.697
Form of metastases (focal vs. all other formsa) 1.9 0.7–5.6 0.230 1.1 0.3–4.3 0.848
a Focal≥diffuse + diffuse>focal + diffuse
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over a long period of time, scan quality might have been
heterogeneous and not equally distributed between the sub-
groups. Therefore our results should be confirmed in a cohort
of patients scanned according to a uniform protocol.
In this study we included only 123I-MIBG scans, but since
Naranjo et al. reported no difference in outcome between
scoring of 123I-MIBG and 131I-MIBG scans [12], it is debat-
able whether 131I-MIBG scans should have been excluded.
However, this project was started many years ago and at that
time 123I-MIBG scans were reported to be of better quality. In
the Cox regression analysis, we included only the COG co-
hort, a homogeneous patient population treated according to
one protocol (COG A3973 protocol). The European cohort
was a heterogeneous cohort because these patients had been
treated according to different protocols, and therefore this was
not an ideal cohort for studying survival. A limitation of the
COG cohort was that not all patients had a follow-up of
5 years. A prospective study including patients from the same
treatment protocol with only digital diagnostic 123I-MIBG
scans performed according to the same scanning procedures
and evaluated by central reviewmight resolve these problems.
In conclusion, our study clearly showed the existence of
two relevant MIBG-avid metastatic patterns in newly diag-
nosed neuroblastoma: an “extensive and diffuse” MIBG-avid
metastatic pattern found mainly in patients with MYCNsc
tumours, and a “limited and focal” pattern found mainly in
patients with MNA tumours. In patients with MNA tumours,
focal metastases had a better prognosis than the other types of
metastases. These two patterns most likely reflect different
biological processes that should be explored further with the
aim of providing a better understanding of the heterogeneous
behaviour of high-risk tumours.
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